Free tool
FAERS Monitor: Bethkis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201820 or its brand name (Bethkis, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
14,537
Serious
11,256
77% of reports
Hospitalization
7,080
Death reported
1,372
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,324
- pneumonia938
- infective pulmonary exacerbation of cystic fibrosis784
- dyspnoea759
- drug ineffective700
- acute kidney injury688
- death575
- hospitalisation550
- cough534
- cystic fibrosis515
- condition aggravated508
- infection491
- pyrexia443
- fatigue424
- diarrhoea400
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 80 |
| 2005 | 97 |
| 2006 | 77 |
| 2007 | 124 |
| 2008 | 91 |
| 2009 | 99 |
| 2010 | 101 |
| 2011 | 208 |
| 2012 | 189 |
| 2013 | 165 |
| 2014 | 273 |
| 2015 | 536 |
| 2016 | 696 |
| 2017 | 762 |
| 2018 | 1,328 |
| 2019 | 2,040 |
| 2020 | 1,899 |
| 2021 | 1,145 |
| 2022 | 1,032 |
| 2023 | 871 |
| 2024 | 1,090 |
| 2025 | 947 |
| 2026 | 687 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,622 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 784 | 243.3 | 226.0 | 161,784 |
| cystic fibrosisSignal | 515 | 148.3 | 135.6 | 68,218 |
| acute kidney injurySignal | 688 | 6.5 | 6.1 | 3,225 |
| hospitalisationSignal | 550 | 5.2 | 4.8 | 1,865 |
| infectionSignal | 491 | 4.9 | 4.5 | 1,536 |
| pneumoniaSignal | 938 | 4.2 | 3.9 | 2,314 |
| coughSignal | 534 | 2.8 | 2.5 | 604 |
| condition aggravatedSignal | 508 | 2.4 | 2.2 | 427 |
| off label useSignal | 1,324 | 2.2 | 2.1 | 890 |
| dyspnoea | 759 | 1.9 | 1.8 | 354 |
| pyrexia | 443 | 1.9 | 1.7 | 176 |
| death | 575 | 1.0 | 0.9 | 1 |
| diarrhoea | 400 | 0.9 | 0.8 | 5 |
| fatigue | 424 | 0.8 | 0.7 | 25 |
| drug ineffective | 700 | 0.8 | 0.7 | 52 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.